A casein-derived active peptide capable of delaying telomere attrition, its application, and a medicine containing the active peptide

By screening out the active peptide FVAPFPE from casein-derived dairy products, the problems of telomeres wear and blood-brain barrier penetration are solved, and anti-inflammatory, antioxidant and aging are achieved. Drug applications that directly enter the brain are used prospect.

CN118702799BActive Publication Date: 2024-11-29THE WEST CHINA SECOND UNIV HOSPITAL OF SICHUAN
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202411161031.5
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-08-22
Publication Date
2024-11-29
Estimated Expiration
2044-08-22

AI Technical Summary

Technical Problem

The prior art is difficult to effectively delay telomeres wear, leading to accelerated aging, and existing drugs are difficult to pass through the blood-brain barrier and directly enter the brain to play a role, which cannot effectively improve the aging and inflammation problems of the nervous system.

Method used

A casein-derived active peptide FVAPFPE was screened from fermented dairy products. It can be used to simulate the digestion and absorption process to ensure that it can enter the brain stably, and has anti-inflammatory and antioxidant functions. It is used to prepare drugs that delay telomeres wear.

Benefits of technology

The active peptide can enter the brain stably, significantly delay telomeres wear, have good anti-inflammatory and antioxidant effects, can prevent or treat aging-related diseases, and improve aging problems in the nervous system.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118702799B_ABST
    Figure CN118702799B_ABST
Patent Text Reader

Abstract

The present invention provides a casein-derived active peptide that can delay telomere wear, its application, and a medicine containing the active peptide, belonging to the technical field of bioactive peptides. The present invention screened an active peptide with a sequence of FVAPFPE from casein hydrolysate prepared by a fermentation method. The active peptide can stably enter the brain after oral ingestion, and has the effects of anti-inflammatory, anti-oxidation, and protection of telomere wear. The active peptide can delay aging, and is expected to be used to prevent and / or treat diseases related to aging, and has good clinical application prospects.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of bioactive peptides, and specifically relates to a casein-derived active peptide capable of delaying telomere wear and an application thereof, and a medicine containing the active peptide. Background Art

[0002] Aging is a progressive, irreversible pathophysiological process, characterized by a decline in tissue and cell function. It is an important risk factor for neurodegenerative diseases, cardiovascular diseases, metabolic diseases, musculoskeletal diseases, and immune system diseases. Telomere shortening, inflammation, and oxidative stress are closely related to the occurrence and development of aging and related diseases. Telomere length is widely used to assess aging. Telomeres continue to shorten during aging, and environmental factors may accelerate or delay this process, thereby accelerating or delaying aging. Mendelian randomization studies have confirmed the causal relationship between telomere length and cognitive function, and between telomere length and Alzheimer's disease. Experimental studies have shown that telomeres are key regulators of age-related neurogenesis and cognitive changes. Delaying telomere wear can help prevent or delay a variety of aging-related diseases.

[0003] There is a complex interactive relationship between telomere shortening, inflammation, and oxidative stress. Telomeres are quite sensitive to inflammation and oxidative stress. Directly inducing oxidative stress at telomeres can promote the activation of DNA damage response and increase telomere fragility, activate the p53 pathway, and accelerate cell aging. Oxidative stress and inflammation promote each other: increased intracellular ROS levels can activate NLRP3 inflammasomes through the oxidative phosphorylation pathway, and can also promote the release of mtDNA by increasing mitochondrial permeability, thereby activating inflammation-related pathways and activating NF-κB to trigger an inflammatory cascade. Double-stranded DNA damage can upregulate NF-κB and thus promote inflammation-related aging phenotypes at the transcriptional level. In addition to NF-κB, Wnt, RAP1, TERT, and PARP proteins also have dual functions in inflammation and telomere maintenance. It can be seen that in understanding the aging process and developing new treatments, it is necessary to explore effective intervention strategies starting from the initiating event.

[0004] Population studies have found that people in the southwest who adhere to a vegetable-based diet have longer telomeres, and yogurt intake contributes significantly to this diet. Animal experiments have compared the effects of yogurt and milk intake on telomere length and found that the yogurt group had longer telomeres than the milk group, and the milk group even had telomere attrition compared to the control group (Shan, SF, Yogurt and Streptococcus thermophilus metabolites ameliorated telomere attrition in D-galactose-induced ageing mice and t-BHP-challenged HepG2 cells, INTERNATIONAL JOURNAL OF FOOD SCIENCE AND TECHNOLOGY, 55(6), 2509-2516). These results suggest that the intake of fermented dairy products may delay aging by delaying telomere attrition, and thus may play a protective role against aging-related diseases. There are a large number of studies on the anti-aging effects of active peptides, and fermentation can also hydrolyze the proteins contained in milk to produce a large number of active peptides. Therefore, fermented dairy products may contain active peptides that are beneficial to cognitive function. In addition, screening active ingredients that can enter the brain from peptides is a direction worth exploring given the current dilemma that most drugs cannot cross the blood-brain barrier. Summary of the invention

[0005] The purpose of the present invention is to provide a casein-derived active peptide capable of delaying telomere wear and application thereof.

[0006] The invention provides an active peptide, the amino acid sequence of which is FVAPFPE.

[0007] The present invention also provides the use of the active peptide in preparing a medicine for delaying telomere wear.

[0008] Furthermore, the drug is a drug for improving telomere attrition in the nervous system.

[0009] Furthermore, the drug is an anti-inflammatory and / or antioxidant drug.

[0010] Furthermore, the drug is a drug for improving oxidative stress and neuroinflammation.

[0011] Furthermore, the drug is a drug for improving cognitive impairment.

[0012] Furthermore, the drug is a drug for delaying aging.

[0013] Furthermore, the drug is a drug for preventing and / or treating diseases associated with aging.

[0014] Furthermore, the drug is a drug that can cross the blood-brain barrier and directly enter the brain to exert its effects.

[0015] The present invention also provides a medicine, which is a preparation prepared by taking the above active peptide as an active ingredient and adding pharmaceutically acceptable excipients or auxiliary ingredients.

[0016] The present invention also provides the use of the active peptide in preparing health food with immunity enhancement or anti-oxidation function.

[0017] The present invention also provides a health food with immunity enhancement or anti-oxidation function, characterized in that it is a product prepared by taking the above-mentioned active peptide as an active ingredient and adding auxiliary materials or auxiliary ingredients acceptable to food.

[0018] Compared with the prior art, the present invention has the following beneficial effects:

[0019] The present invention screened an active peptide with the sequence FVAPFPE from casein hydrolysate prepared by fermentation through in vitro simulation of the in vivo process after human ingestion, molecular docking prediction and cell experiment verification. The active peptide can stably enter the brain after oral ingestion and has the effects of anti-inflammatory, anti-oxidation and protection of telomere wear. The active peptide can delay aging and is expected to be used to prevent and / or treat diseases related to aging, and has good clinical application prospects.

[0020] The present invention provides a casein-derived active peptide that is expected to directly enter the brain and improve telomere wear, oxidative stress and neuroinflammation in the nervous system. It can be used to prepare drugs for improving aging, oxidative stress and inflammation in the nervous system, and can also be used in combination with other health products or food additives. The active peptide developed by the present invention has a clear structure, can be chemically synthesized, has a low synthesis cost, and is derived from casein derived from natural cow's milk, has good biocompatibility and high safety.

[0021] Obviously, according to the above contents of the present invention, in accordance with common technical knowledge and customary means in the art, without departing from the above basic technical ideas of the present invention, other various forms of modification, replacement or change may be made.

[0022] The above contents of the present invention are further described in detail below through specific implementation methods in the form of embodiments. However, this should not be understood as the scope of the above subject matter of the present invention being limited to the following examples. All technologies realized based on the above contents of the present invention belong to the scope of the present invention. BRIEF DESCRIPTION OF THE DRAWINGS

[0023] Figure 1 The figure shows the toxic effects of seven peptides on BV2 cells.

[0024] Figure 2This is a graph showing the effects of seven peptides on NO production in BV2 cells induced by lipopolysaccharide.

[0025] Figure 3 The graph shows the effects of peptides FVAPFPE (FE7) and FGKEKVNE (FE8) on IL-1β levels.

[0026] Figure 4 The figure shows the effects of peptides FVAPFPE (FE7) and FGKEKVNE (FE8) on ROS levels.

[0027] Figure 5 This is a graph showing the effects of peptides FVAPFPE (FE7) and FGKEKVNE (FE8) on MDA levels.

[0028] Figure 6 This is the result of the identification of primary neural stem cells from rats. A. Feature 1: Ability to divide asymmetrically; B. Feature 2: Ability to divide and proliferate; C. Feature 3: Positive expression of the stem cell characteristic protein Nestin; D. Feature 4: Positive expression of the differentiation marker protein GFAP.

[0029] Figure 7 This figure shows the cytotoxicity of neural stem cells after intervention with different concentrations of tert-butyl hydrogen peroxide for 48 h.

[0030] Figure 8 The figure shows the cytotoxicity results of the peptide FVAPFPE at different concentrations on neural stem cells after intervention for 48 hours.

[0031] Fig. 9 This figure shows the effect of peptide FVAPFPE intervention on telomere length under oxidative stress conditions. DETAILED DESCRIPTION

[0032] In the specific embodiments of the present invention, experimental methods without specific conditions are based on conventional conditions or conditions recommended by manufacturers unless otherwise specified, and various commonly used chemical reagents used are all commercially available products.

[0033] Example 1: Screening of brain-active peptides derived from casein

[0034] The present invention adopts a simple and efficient method to screen brain-entering active peptides from casein hydrolysate fermented by Lactobacillus bulgaricus. After the fermented casein hydrolysate is prepared, the following three steps of simulating digestion, absorption and transport in vitro are carried out in sequence: (1) the INFOGEST standard method simulates the human digestion process; (2) based on culturing human colon cancer cells (Caco-2) on transwell chambers to form a barrier to simulate the human intestinal absorption process; (3) based on culturing immortalized human brain microvascular endothelial cells (hCMEC / D3) on transwell chambers to form a barrier to simulate the human blood-brain barrier permeation process.

[0035] Casein hydrolysate was prepared by mixed fermentation with the standard strain of Lactobacillus bulgaricus (Genbank sequence number: CP032451.1). After Lactobacillus bulgaricus was revived and subcultured twice for activation, it was added to sterilized MRS liquid medium at a ratio of 1%-2% and mixed, and then placed in an anaerobic incubator at 37°C for 36 h for bacterial amplification. After the culture was completed, the bacterial solution was centrifuged and concentrated, and the plate count was performed according to the national standard method. The concentrated bacterial solution was added to a sterile 50 mL centrifuge tube, centrifuged at 3000 rpm / min for 10 min at 4°C, and the supernatant was discarded. Then 3 times the volume of PBS was added for washing, and centrifuged at 3000 rpm / min for 10 min at 4°C, and the PBS was discarded for later use. Weigh casein solid in a beaker at a ratio of 2.5 g casein / 100 mL ultrapure water, add 0.5 M NaOH solution at 4% (v / v) and stir thoroughly, then add 96% (v / v) ultrapure water, seal with sealing film, stir magnetically at room temperature, wait until the clumping casein is completely dissolved, and measure the pH between 7.2-7.3, heat at 90°C for 15 min to sterilize, wait until it cools to room temperature, take 5 mL of casein solution to resuspend the prepared bacteria, then add a certain amount of casein solution and mix well to make the bacterial solution concentration reach 5×10 8 CFU / mL, then screw on the centrifuge tube cap, seal with sealing film and place in 37 ℃ anaerobic incubator for fermentation for 72 h. The fermentation system was centrifuged at 4 ℃ and 3900 rpm / min for 10 min, filtered and sterilized with a 0.22 um membrane to prepare the "fermented casein hydrolysate", which was freeze-dried and used in the next experiment.

[0036] (1) INGEST standard method simulates the human digestion process

[0037] This part is carried out in full accordance with the standard operating procedures required by INFOGEST version 2.0. In short, the stock solution was prepared first, and then the digestion solution was prepared according to the amount of stock solution in each digestion solution. After the preparation was completed, it was preheated to 37°C for use. During the heating process, it was sealed with a sealing film to prevent the solvent from evaporating. Then 120 mg of freeze-dried casein hydrolyzate was weighed and dissolved in 3 mL of the prepared oral digestion solution. It was shaken at 60 rpm / min at 37°C for 2 min to simulate the oral digestion stage. Next, 3 mL of gastric digestion fluid containing 2000 U / mL pepsin was added to the system, and the timing began from the time the enzyme was added. The system was placed in a 37°C incubator and shaken at a horizontal speed of 60 rpm / min for 120 min; next, 6 mL of intestinal digestion fluid containing 100 U / mL trypsin and 200 mg / mL bile was added to the system, and the timing began from the time the enzyme was added. The system was placed in a 37°C incubator and shaken at a horizontal speed of 60 rpm / min for 120 min; after the digestion was completed, after inactivation at 100°C for 5 min, all the liquid was added to a 10 kDa ultrafiltration tube, and centrifuged at 3000 rpm / min at 4°C for 15 min to eliminate the interference of digestive enzymes, and the filtrate <10 kDa was collected as the "simulated digestion product".

[0038] (2) Human colon cancer cells (Caco-2) form a barrier to simulate the human intestinal absorption process

[0039] Caco-2 cells were cultured in DMEM high-glucose medium supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin, and passaged every 2-3 days. 5 The cells were added to the top side of the transwell chamber (corning, 3470, membrane diameter 6.5 mm, membrane pore size 0.4 um) at a density of 0.1 mL in a volume, and 0.6 mL of culture medium was added to the basolateral side. Caco-2 cells were cultured on the transwell chamber for 21 days to grow into a complete and dense monolayer. During this period, the transmembrane resistance on both sides of the membrane was monitored and the medium was replaced every 2 days using a Millicell-ERS 2 cell resistance meter. The toxic effect of the test substance on the cells was detected by the CCK-8 method. B was diluted in Hank's balanced salt solution (HBSS) at the maximum non-toxic concentration and then added to the top side of the transwell chamber. Fresh HBSS was received on the basolateral side for 2 hours, the basolateral liquid was collected, and the transmembrane resistance was detected. The transmembrane resistance of the Caco-2 cell barrier was maintained at 400 Ω·cm 2 The above holes are effective holes, and the products after transport through the effective holes are collected as the "simulated intestinal absorption part".

[0040] (3) Immortalized human brain microvascular endothelial cells (hCMEC / D3) form a barrier to simulate the permeation process of the human blood-brain barrier

[0041] hCMEC / D3 cells were cultured in hCMEC / D3-specific medium (PriMed-iCell-002, formula: 93% endothelial cell culture basal medium, 5% high-quality fetal bovine serum, 1% endothelial cell culture additive, 1% penicillin / streptomycin) and passaged when the cell density reached 80-90%. The well-growing cell suspension was cultured at 2×10 5 Cells were added to the top side of a transwell chamber (corning, 3470, membrane diameter 6.5 mm, membrane pore size 0.4 um) at a density of 0.1 mL in a volume. At the same time, 0.6 mL of culture medium was added to the basolateral side. The medium was changed every 2 days. The cells were cultured on the transwell chamber for 7 days to form a complete monolayer. During this period, the transmembrane resistance on both sides of the membrane was monitored once every 2 days using a Millicell-ERS 2 cell resistance meter. The standard of the TEER value of this part was ≥20 Ω·cm 2 At the same time, the toxic effect of the intervention of "simulated intestinal absorption into the blood" on hCMEC / D3 cells was detected, and the maximum non-toxic concentration was selected for transport experiments. The "simulated intestinal absorption into the blood" was diluted in HBSS solution at this concentration, and then added to the top side of the transwell chamber, and received from the basal side for 2 h. After collecting the basal side liquid, the transmembrane resistance was detected again, and the transmembrane resistance of the hCEMC / D3 cell barrier was maintained at 20 Ω·cm 2 The above holes are effective holes, and the products transported through the effective holes are called "the part simulating menstrual blood entering the brain".

[0042] The "fermented casein hydrolysate", "simulated digestion products", "simulated intestinal absorption into the blood", and "simulated blood into the brain" were subjected to peptide group detection. After peptide identification, the intersection of these four stages was found to characterize the subset of peptides in the casein hydrolysate prepared by Lactobacillus bulgaricus fermentation that can resist the destruction of the digestive process, withstand the hydrolysis of enzymes secreted by intestinal epithelial cells on the intestinal side, and can completely pass through the intestinal epithelial barrier and the blood-brain barrier. The above results contain 63 peptides. Next, the above 63 peptides were molecularly docked with the active site Ketch domain of Keap1 protein (https: / / www.rcsb.org / structure / 2FLU) using Autodock vina. In theory, this active peptide can promote the release of Nrf2 by competing with Nrf2 for targets, thereby initiating downstream antioxidant and crosstalk processes with inflammatory responses. We sorted the above 63 peptides by docking scores, and used the docking score of Nrf2, the original ligand of Keap1 protein, -7.8kcal / mol as the cutoff point to identify 7 peptides with docking scores lower than -7.8 kcal / mol and molecular weight less than 1 kDa (the sequence information of these 7 peptides is shown in Table 1). Searching the two active peptide databases BIOPEP-UWM (https: / / www.uwm.edu.pl / biochemia) and the Milk Bioactive Peptide Database (https: / / mbpdb.nws.oregonstate.edu / ) found that these 7 peptides had no records yet, so it can be considered that these 7 peptides are all newly discovered sequences. These 7 peptides were predicted to be non-toxic by ToxiBTL (http: / / server.wei-group.net / ToxIBTL). The peptide ranker tool (http: / / distilldeep.ucd.ie / PeptideRanker / ) predicted that FVAPFPE and PVVVPPF may have biological activity.

[0043] Table 1. Information of 7 peptides with potential biological activity screened out

[0044]

[0045] Example 2: Verification of prediction results in a mouse microglial cell line BV2 cell model

[0046] The above 7 peptides were artificially synthesized and desalted by using solid phase synthesis method in Shanghai Bioengineering Co., Ltd. The purity of the synthesized peptides was >99% as measured by reverse phase high performance liquid chromatography.

[0047] 2.1 Toxicity of peptides screened in vitro to BV2 cells and their effects on NO production

[0048] BV2 cells were cultured in DMDM ​​medium containing 10% fetal bovine serum and 1% penicillin-streptomycin in a 37°C, 5% CO2 incubator and passaged every 1-2 days. 5 The cells were plated in a 96-well plate at a density of 100 μL per well. After the cells grew for 24 h, they were intervened with peptides at concentrations of 0.01 μg / mL, 0.1 μg / mL, 1.00 μg / mL, and 10.00 μg / mL for 24 h. The cell survival rate was detected by CCK-8 method, and the experiment was repeated 3 times.

[0049] The results are as follows Figure 1 As shown, none of the seven peptides showed cytotoxicity to BV2 cells.

[0050] The Griess method was used to detect NO production and evaluate the effects of the seven peptides screened in vitro on lipopolysaccharide-induced neuroinflammation in BV2 cells. 5 The cells were plated in 96-well plates at a density of 1 μg / mL, with 100 μL per well. After the cells grew for 24 h, the treatment measures of each group were as follows: control group: no peptide or lipopolysaccharide was added, and the same amount of culture medium was supplemented; model group: no peptide was added, and lipopolysaccharide with a final concentration of 1 μg / mL was added; positive control group: lipopolysaccharide with a final concentration of 1 μg / mL and curcumin with a final concentration of 5 μM were added; intervention group: lipopolysaccharide with a final concentration of 1 μg / mL and 1.00 μg / mL of peptide were added. Each group was intervened for 24 h. The cell supernatant was collected, and the NO generation was detected by Griess method.

[0051] The NO test results are as follows Figure 2 As shown in the figure, compared with the unintervention control group, the NO production in the model group increased significantly, and the NO production in the positive control group decreased significantly (Curcumin is a recognized natural medicine with antioxidant and anti-inflammatory activities, which also helps to delay aging, but it cannot cross the blood-brain barrier). In the peptide intervention groups, the two peptides FVAPFPE (FE7) and FGKEKVNE (FE8) significantly reduced the production of nitric oxide (NO), and the other five peptides did not show an inhibitory effect on NO. Therefore, in subsequent experiments, only the effects of these two peptides were evaluated.

[0052] 2.2 Evaluation of the anti-inflammatory and antioxidant effects of peptides that reduce NO production

[0053] BV2 cells were cultured at 1×10 5The cells were plated in 96-well plates at a density of 1 μg / mL, with 100 μL per well. After the cells grew for 24 h, the treatment measures of each group were as follows: control group: no peptide or lipopolysaccharide was added, and the same amount of culture medium was supplemented; model group: no peptide was added, and lipopolysaccharide with a final concentration of 1 μg / mL was added; positive control group: lipopolysaccharide with a final concentration of 1 μg / mL and curcumin with a final concentration of 5 μM were added; intervention group: lipopolysaccharide with a final concentration of 1 μg / mL and peptides of different concentrations (0.01 μg / mL, 0.1 μg / mL, 1.00 μg / mL) were added. Each group was intervened for 24 h. The cell supernatant was collected, and the IL-1β content was detected by ELISA kit.

[0054] IL-1β test results Figure 3 As shown in the figure, the IL-1β production in the model group indicated that LPS induced BV2 cells to release more IL-1β, and after intervention with different concentrations of FVAPFPE, the IL-1β production tended to decrease with the increase of peptide concentration. The decrease in IL-1β production after peptide intervention was most obvious in the 1.00 μg / mL dose group, and the difference was statistically significant. However, FGKEKVNE intervention did not reduce the IL-1β level.

[0055] BV2 cells were cultured at 1×10 5 The cells were plated in 24-well plates at a density of 500 μL / mL, and the intervention was started after 24 h of culture. The treatment measures of each group were as follows: control group: no peptide or lipopolysaccharide was added, and the same amount of culture medium was supplemented; model group: no peptide was added, and only lipopolysaccharide with a final concentration of 1 μg / mL was added; positive control group: lipopolysaccharide with a final concentration of 1 μg / mL and curcumin with a final concentration of 5 μM were added; intervention group: lipopolysaccharide with a final concentration of 1 μg / mL and peptides of different concentrations (0.01 μg / mL, 0.1 μg / mL, 1.00 μg / mL) were added. Each group was intervened for 24 h. ROS levels were detected by enzyme-labeled method using ROS detection kit (Biyuntian). Specifically, DCFH-DA was diluted 1:1000 with serum-free DMEM to a final concentration of 10 μmol / L. After removing the cell culture medium on the 24-well plate, the diluted DCFH-DA was added, and the cells were incubated in a 37ºC incubator for 20 min. After scraping the cells, wash the cells three times with serum-free cell culture medium, mix the cells and divide them into two parts. One part is detected by fluorescence microplate reader under the conditions of 488 nm excitation wavelength and 525 nm emission wavelength. The other part is detected by CCK-8 method for absorbance at 450 nm. The ratio of fluorescence intensity to absorbance at 450 nm is calculated and corrected with the value of the control group to obtain the relative ROS value.

[0056] ROS detection results are as follows Figure 4As shown in the figure, the decrease in ROS in the positive control group was statistically significant compared with the model group; FVAPFPE (1 μg / mL) intervention also significantly decreased ROS, which was statistically significant compared with the model group. The intervention effect of 1 μg / mL FVAPFPE was equivalent to the positive control level, which suggests that 1 μg / mL FVAPFPE has almost the same ROS scavenging ability as 5 μM curcumin. However, there was no statistical difference in the relative ROS after FGKEKVNE intervention with the model group.

[0057] BV2 cells were cultured at 1×10 5 The cells were plated in 6-well plates at a density of 1 μg / mL, with 3 mL per well. The intervention was started after 24 h of culture. The treatment measures of each group were as follows: control group: no peptide or lipopolysaccharide was added, and the same amount of culture medium was supplemented; model group: no peptide was added, only lipopolysaccharide with a final concentration of 1 μg / mL was added; positive control group: lipopolysaccharide with a final concentration of 1 μg / mL and curcumin with a final concentration of 5 μM were added; intervention group: lipopolysaccharide with a final concentration of 1 μg / mL and peptides of different concentrations (0.01 μg / mL, 0.1 μg / mL, 1.00 μg / mL) were added. Each group was intervened for 24 h. After the intervention, the cells were scraped with a cell scraper, lysed, and protein quantification was performed using a BCA kit (Biyuntian). The MDA level was detected using an MDA detection kit (Biyuntian). The experimental operation was carried out in full accordance with the instructions.

[0058] MDA test results Figure 5 As shown in the figure, the MDA level of the model group increased significantly after LPS induction of BV2 cells. After intervention with different concentrations of FVAPFPE, the MDA level tended to decrease with the increase of peptide concentration. The decrease was most obvious in the 1.00 μg / mL FVAPFPE intervention group, and the difference was statistically significant compared with the model group. However, there was no statistical difference between the MDA level after FGKEKVNE intervention and the model group.

[0059] In summary, this section functionally validated the seven small peptides screened by molecular docking, and the results showed that FVAPFPE had the best effect and had both anti-inflammatory and antioxidant capabilities. 1 μg / mL FVAPFPE was as effective as 5 μM curcumin in improving IL-1β, ROS, and MDA levels.

[0060] Example 3: Effect of FVAPFPE on relative telomere length of neural stem cells from SD rats

[0061] Aging in the natural state is accompanied by a shortening of telomere length, and oxidative stress can accelerate telomere wear and aging. Therefore, based on the close relationship between oxidative stress and telomeres in neurodegenerative diseases, the present invention focuses on the protective effect of the above-mentioned FVAPFPE screened for antioxidant and anti-inflammatory activity against telomere wear accelerated by oxidative stress.

[0062] 3.1 Isolation, culture and identification of neural stem cells

[0063] The hippocampus of SD rats within 24 hours after birth was isolated under sterile conditions and mechanically digested, then cultured in DMEM / F12 medium (supplemented with 2% B27, 1% penicillin-streptomycin, 20 ng / mL epidermal growth factor, and 20 ng / mL basic fibroblast growth factor). The medium was changed every 2 days. After 7 days of culture, the cells were digested with Accutase and counted to obtain neural stem cells. The morphological characteristics, division ability, and proliferation ability of neural stem cells were observed under a microscope, and the surface marker proteins were identified by immunofluorescence. In the immunofluorescence experiment, after incubation with Nestin and GFAP antibodies, green-labeled secondary antibodies were added, and the cell nuclei were labeled with DAPI staining solution. Then the cells were observed under a fluorescence microscope.

[0064] The results are as follows Figure 6 As shown, through the morphological characteristics of neural stem cells, a single nerve cell is round, has the typical asymmetric division ability of neural stem cells, has the symmetric division and proliferation ability, Nestin staining results are positive, indicating that it has the characteristics of stem cells, and its surface GFAP staining results are positive, indicating that the cell has differentiation ability. The above characteristics indicate that the cells obtained in the above manner have the characteristics of neural stem cells.

[0065] 3.2 Selection of tert-butyl hydrogen peroxide modeling dosage

[0066] Neural stem cells were cultured at 2×10 5 The density of cells / mL was plated in a 96-well plate, with 100 μL per well. After the cells grew for 24 hours, they were intervened with tert-butyl hydroperoxide at different concentrations (0 μM, 10 μM, 20 μM, 40 μM, 50 μM, and 60 μM final concentration) for 48 hours, and the cell survival rate was detected by CCK-8 method. The experiment was repeated 3 times.

[0067] The results are as follows Figure 7 As shown, when the concentration of tert-butyl hydroperoxide is 20 μM, the survival rate of primary neural stem cells is about 80%. Combined with the modeling concentration reported in the literature, the present invention adopts 20 μM as the modeling dose.

[0068] 3.3 Cytotoxicity test of peptide FVAPFPE on neural stem cells

[0069] The source and acquisition method of neural stem cells are the same as 3.1. Primary neural stem cells were cultured at 2×10 5 The cells were plated in a 96-well plate at a density of 100 μL per well. After the cells grew for 24 h, they were intervened with FVAPFPE at concentrations of 0.01 μg / mL, 1.00 μg / mL, and 100.00 μg / mL for 48 h. The cell survival rate was detected by CCK-8 method, and the experiment was repeated 3 times.

[0070] The results are as follows Figure 8 As shown in the data, FVAPFPE had no cytotoxicity within the dose range of 0.01-100.00 μg / mL. Therefore, this experiment was further tested within this dose range.

[0071] 3.4 Detection of telomere length after peptide FVAPFPE intervention

[0072] The source and acquisition method of neural stem cells were the same as in 3.1. Neural stem cells from SD rats were collected at 2×10 5 The cells were cultured in T25 culture flasks at a density of 5 mL / mL. FVAPFPE was added to serum-free DMEM / F12 medium at a final concentration of 0.01 μg / mL, 0.1 μg / mL, and 1 μg / mL. 5 μM curcumin was used as a positive control. The medium was completely changed every 2 days. After 10 days of continuous intervention, the medium was replaced with DMEM / F12 medium supplemented with 20 μM tert-butyl hydroperoxide. After 48 hours of modeling, genomic DNA was extracted and diluted to 50 ng / μL. Relative telomere length was detected by qt-PCR. A 10 μL reaction system was prepared with 0.4 μL 10 μM forward primer, 0.4μl 10 μM negative primer, 3.2 μL ddH2O, 5 μL TaqII, and 1 μL genomic DNA (reverse transcription reagents and PCR reaction system reagents were purchased from Takara). LightCycler96 real-time quantitative PCR instrument was used for detection. The qt-PCR reaction conditions were as follows: 95°C pre-denaturation for 3 min, followed by 95°C denaturation for 10 s, 60°C annealing for 30 s, and 72°C extension for 40 s, for a total of 40 cycles, with AT1 as an internal reference. The experiment was repeated 3 times, and each sample was tested 3 times.

[0073] The primer sequences are as follows:

[0074] Telo-F: GGTTTTTGAGGGTGAGGGTGAGGGTGAGGGTGAGGGT (SEQ ID NO.8)

[0075] Telo-R:TCCCGACTATCCCTATCCCTATCCCTATCCCTATCCCTA (SEQ ID NO.9)

[0076] AT1-F: ACGTGTTCCAGCATCGACCCTACC (SEQ ID NO.10)

[0077] AT1-R: AGAATGATAAGGAAAGGGAAGAAGCCC (SEQ ID NO.11)

[0078] The results are as follows Fig. 9 As shown: Compared with the control group, the model group (t-BHP intervention group) neural stem cells were shortened after being treated with tert-butyl hydrochloride. After 10 days of active peptide pretreatment, the relative telomere length of the three intervention groups was longer than that of the model group, and the relative telomere length after 0.10 μg / mL peptide FVAPFPE intervention was statistically significant compared with the model group. This indicates that peptide FVAPFPE can delay telomere attrition.

[0079] In summary, the present invention screened an active peptide with the sequence of FVAPFPE from casein hydrolysate prepared by fermentation. After in vitro simulation, molecular docking prediction and cell experiment verification, it was confirmed that the active peptide can stably enter the brain after oral intake, and has anti-inflammatory, antioxidant and telomere wear protection effects. The active peptide can delay aging, and prevent and / or treat diseases related to aging, and has good clinical application prospects.

Claims

1. Use of an active peptide in the preparation of a drug for improving neuroinflammation, characterized in that: The amino acid sequence of the active peptide is FVAPFPE.

Citation Information

Patent Citations

  • Milk protein hydrolyzates with reduced immunogenic potential

    CN101594785A

  • Application of yoghourt derived polypeptide in preparation of telomere shortening delaying medicine and anti-aging medicine

    CN115252759A